Analysts Have Just Cut Their Camurus AB (publ) (STO:CAMX) Revenue Estimates By 11%
Market forces rained on the parade of Camurus AB (publ) (STO:CAMX) shareholders today, when the analysts downgraded their forecasts for next year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.
Following the downgrade, the current consensus from Camurus' seven analysts is for revenues of kr3.7b in 2026 which - if met - would reflect a sizeable 56% increase on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of kr4.1b in 2026. The consensus view seems to have become more pessimistic on Camurus, noting the measurable cut to revenue estimates in this update.
Check out our latest analysis for Camurus
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Camurus' past performance and to peers in the same industry. It's clear from the latest estimates that Camurus' rate of growth is expected to accelerate meaningfully, with the forecast 43% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 35% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 27% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Camurus is expected to grow much faster than its industry.
The Bottom Line
The clear low-light was that analysts slashing their revenue forecasts for Camurus next year. Analysts also expect revenues to grow faster than the wider market. Overall, given the drastic downgrade to next year's forecasts, we'd be feeling a little more wary of Camurus going forwards.
Still got questions? We have estimates for Camurus from its seven analysts out until 2027, and you can see them free on our platform here.
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:CAMX
Camurus
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
Exceptional growth potential with flawless balance sheet.
Similar Companies
Market Insights
Community Narratives

